Compare Novo Nordisk A/S (NVO) vs Paycom Software Inc (PAYC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Paycom Software Inc — how do they compare? Novo Nordisk A/S trades at $46.25 (market cap $207.85B), while Paycom Software Inc trades at $207 (market cap $9.57B). The key difference: Novo Nordisk A/S is far larger — about 21.7× Paycom Software Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| NVO | PAYC | |
|---|---|---|
Market Cap | $207.85B | $9.57B |
Sector | Health | Technology |
52-Week High | $63.98 | $233.89 |
52-Week Low | $35.29 | $113.59 |
Enterprise Value | $222.55B | $10.35B |
Dividend Yield | 3.81% | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Paycom Software (PAYC) trades at $206.16, down 3.42% today but maintains strong fundamentals with consistent earnings beats and robust profitability. The stock shows bullish technical momentum with recent Q2 2026 results exceeding expectations, driven by 10% revenue growth and margin expansion. AI-driven demand and automation savings support management's raised 2026 outlook.
Outlook remains positive with analyst consensus target of $219.22 offering 6% upside. Key risks include valuation multiples above sector averages and competitive pressures. The company's strong cash flow generation and dividend payments provide shareholder value support amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
